Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Breelyn Wilky

Concepts (268)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma
22
2026
207
8.020
 Why?
Gastrointestinal Stromal Tumors
7
2026
41
2.980
 Why?
Soft Tissue Neoplasms
9
2024
131
2.830
 Why?
Molecular Targeted Therapy
9
2026
440
1.770
 Why?
Precision Medicine
4
2026
461
1.700
 Why?
Antineoplastic Combined Chemotherapy Protocols
7
2025
1969
1.550
 Why?
Immunotherapy
10
2023
667
1.520
 Why?
Bone Neoplasms
9
2025
265
1.470
 Why?
Sarcoma, Alveolar Soft Part
2
2023
6
1.360
 Why?
Hemangiosarcoma
2
2021
25
1.200
 Why?
Gastrointestinal Neoplasms
2
2026
73
1.150
 Why?
CTLA-4 Antigen
2
2025
105
1.080
 Why?
Antineoplastic Agents
9
2026
2219
1.000
 Why?
Neoplasm Recurrence, Local
4
2025
1150
0.900
 Why?
Biomarkers, Tumor
8
2022
1329
0.900
 Why?
Circulating Tumor DNA
2
2022
46
0.730
 Why?
Antibodies, Monoclonal, Humanized
6
2025
992
0.730
 Why?
Leiomyosarcoma
1
2022
29
0.720
 Why?
Pyrimidines
2
2018
530
0.710
 Why?
Sulfonamides
2
2018
583
0.690
 Why?
Chondrosarcoma
4
2025
17
0.650
 Why?
Giant Cell Tumor of Tendon Sheath
3
2026
9
0.630
 Why?
Sarcoma, Ewing
2
2025
103
0.610
 Why?
Immunomodulation
2
2019
99
0.580
 Why?
Humans
66
2026
145763
0.570
 Why?
Antineoplastic Agents, Immunological
3
2019
198
0.550
 Why?
Combined Modality Therapy
7
2026
1270
0.550
 Why?
Salvage Therapy
1
2019
165
0.540
 Why?
Neoplasms
5
2024
2913
0.470
 Why?
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
2
2026
17
0.460
 Why?
Medical Oncology
3
2025
340
0.460
 Why?
Imatinib Mesylate
2
2026
77
0.440
 Why?
Neovascularization, Pathologic
1
2017
287
0.440
 Why?
DEAD-box RNA Helicases
1
2015
84
0.430
 Why?
Programmed Cell Death 1 Receptor
3
2025
266
0.430
 Why?
Protein Kinase Inhibitors
5
2026
981
0.410
 Why?
Diffusion Magnetic Resonance Imaging
1
2015
156
0.410
 Why?
Prognosis
8
2025
4329
0.400
 Why?
Solitary Fibrous Tumors
1
2013
3
0.400
 Why?
Thoracic Neoplasms
1
2013
39
0.390
 Why?
Liposarcoma
2
2023
31
0.370
 Why?
Sarcoma, Synovial
2
2024
20
0.360
 Why?
Treatment Outcome
12
2026
11793
0.350
 Why?
Adult
23
2026
40872
0.340
 Why?
Giant Cell Tumor of Bone
2
2021
8
0.340
 Why?
Antigens, Neoplasm
2
2024
271
0.320
 Why?
Bone Density Conservation Agents
2
2021
82
0.310
 Why?
Magnetic Resonance Imaging
3
2021
3915
0.300
 Why?
Brain Neoplasms
1
2019
1331
0.300
 Why?
Middle Aged
18
2026
36302
0.290
 Why?
Disease Management
2
2026
653
0.280
 Why?
Aged
15
2026
26215
0.280
 Why?
Melanoma
2
2025
761
0.280
 Why?
Isocitrate Dehydrogenase
3
2025
72
0.270
 Why?
Doxorubicin
2
2025
403
0.270
 Why?
Receptor, Platelet-Derived Growth Factor alpha
2
2019
53
0.270
 Why?
T-Lymphocytes
4
2026
1997
0.260
 Why?
Male
21
2026
73003
0.260
 Why?
Imidazoles
3
2023
247
0.250
 Why?
Ovarian Neoplasms
2
2025
595
0.250
 Why?
Female
22
2026
79035
0.240
 Why?
Receptors, Fibroblast Growth Factor
1
2026
70
0.230
 Why?
Succinate Dehydrogenase
1
2026
65
0.230
 Why?
Mutation
6
2025
4090
0.230
 Why?
Neoplasm Metastasis
4
2025
688
0.230
 Why?
Protein Tyrosine Phosphatase, Non-Receptor Type 22
1
2025
48
0.230
 Why?
Interleukin-1 Receptor-Associated Kinases
1
2025
41
0.230
 Why?
Indazoles
2
2018
85
0.220
 Why?
Liquid Biopsy
2
2022
15
0.220
 Why?
DNA-Activated Protein Kinase
1
2024
14
0.220
 Why?
Receptors, Antigen, T-Cell
2
2026
673
0.210
 Why?
Hemangioendothelioma, Epithelioid
1
2024
7
0.210
 Why?
Denosumab
2
2021
11
0.210
 Why?
Osteosarcoma
1
2025
89
0.210
 Why?
Liposarcoma, Myxoid
1
2024
10
0.210
 Why?
Sodium Tetradecyl Sulfate
1
2024
2
0.210
 Why?
Oncologists
1
2025
47
0.210
 Why?
Cell Line, Tumor
7
2026
3551
0.210
 Why?
Electroporation
1
2024
43
0.200
 Why?
Young Adult
10
2026
14251
0.200
 Why?
Tumor Microenvironment
4
2025
735
0.200
 Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2023
31
0.200
 Why?
Cancer Vaccines
3
2019
162
0.190
 Why?
Tetrahydronaphthalenes
1
2023
34
0.190
 Why?
Job Satisfaction
1
2025
238
0.180
 Why?
Anemia
1
2024
191
0.180
 Why?
Neoplasms, Second Primary
1
2023
102
0.180
 Why?
Thrombocytopenia
1
2024
204
0.180
 Why?
Cytotoxicity, Immunologic
2
2019
224
0.180
 Why?
Academic Medical Centers
1
2025
554
0.170
 Why?
Survival Rate
2
2019
2094
0.170
 Why?
Response Evaluation Criteria in Solid Tumors
1
2021
21
0.170
 Why?
Quinazolines
1
2023
266
0.170
 Why?
Translocation, Genetic
2
2019
120
0.170
 Why?
Clinical Trials, Phase II as Topic
3
2019
75
0.170
 Why?
Animals
12
2026
38097
0.170
 Why?
Immunotherapy, Adoptive
2
2026
342
0.160
 Why?
Postoperative Complications
1
2013
2977
0.160
 Why?
beta Catenin
1
2022
254
0.160
 Why?
Osteoblasts
1
2021
145
0.150
 Why?
Chromosomes, Human, Pair 12
1
2019
22
0.150
 Why?
Chromosomes, Human, Pair 7
1
2019
17
0.150
 Why?
Zinc Finger Protein GLI1
1
2019
25
0.150
 Why?
Gene Fusion
1
2019
30
0.150
 Why?
Oncogene Fusion
1
2019
11
0.150
 Why?
Immunity, Innate
1
2025
835
0.150
 Why?
Chemoradiotherapy
1
2021
239
0.150
 Why?
Neoplasm Staging
4
2018
1474
0.150
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2019
86
0.150
 Why?
Gene Amplification
1
2019
118
0.150
 Why?
Retrospective Studies
6
2024
17325
0.150
 Why?
High-Throughput Nucleotide Sequencing
1
2022
534
0.140
 Why?
Tumor Escape
1
2019
49
0.140
 Why?
Indoles
1
2023
507
0.140
 Why?
Transcriptome
1
2025
1042
0.140
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
7
0.140
 Why?
Neurofibrosarcoma
1
2018
7
0.140
 Why?
Carcinogenesis
1
2019
228
0.130
 Why?
Receptor Protein-Tyrosine Kinases
1
2019
231
0.130
 Why?
Liver Neoplasms
1
2024
777
0.130
 Why?
Hematology
1
2017
21
0.130
 Why?
Drug Resistance, Neoplasm
2
2025
883
0.130
 Why?
Aged, 80 and over
6
2025
8346
0.130
 Why?
Radiography
2
2021
853
0.130
 Why?
Actins
1
2019
426
0.130
 Why?
Gene Expression Regulation, Neoplastic
3
2025
1450
0.130
 Why?
Drug Administration Schedule
1
2019
782
0.130
 Why?
T-Lymphocyte Subsets
1
2019
420
0.120
 Why?
Follow-Up Studies
2
2019
5428
0.120
 Why?
Rhabdoid Tumor
1
2018
102
0.120
 Why?
Quality of Life
2
2026
3210
0.120
 Why?
Clinical Trials as Topic
1
2021
1062
0.120
 Why?
Colorectal Neoplasms
1
2024
868
0.120
 Why?
Receptor, Macrophage Colony-Stimulating Factor
2
2026
12
0.120
 Why?
Glutarates
1
2015
11
0.110
 Why?
Benzeneacetamides
1
2015
8
0.110
 Why?
Drug Discovery
1
2017
153
0.110
 Why?
Lymphocytes, Tumor-Infiltrating
3
2024
153
0.110
 Why?
Mice
7
2026
18355
0.110
 Why?
Simulation Training
1
2017
136
0.110
 Why?
Azepines
1
2015
105
0.110
 Why?
Gene Knockdown Techniques
1
2015
334
0.110
 Why?
Receptor, IGF Type 1
1
2014
64
0.110
 Why?
Apoptosis
3
2023
2443
0.100
 Why?
MAP Kinase Kinase Kinases
1
2014
70
0.100
 Why?
Paired Box Transcription Factors
1
2014
43
0.100
 Why?
Chordoma
1
2013
17
0.100
 Why?
Tomography, X-Ray Computed
1
2024
2770
0.100
 Why?
Macrophages
1
2021
1507
0.100
 Why?
Fellowships and Scholarships
1
2017
354
0.100
 Why?
TOR Serine-Threonine Kinases
1
2017
456
0.100
 Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2016
346
0.100
 Why?
Benzimidazoles
1
2014
189
0.100
 Why?
Clinical Trials, Phase III as Topic
1
2013
116
0.100
 Why?
Rhabdomyosarcoma
1
2014
65
0.100
 Why?
Drug Screening Assays, Antitumor
1
2013
194
0.100
 Why?
Membrane Proteins
1
2019
1166
0.090
 Why?
Genetic Predisposition to Disease
2
2019
2399
0.090
 Why?
Forkhead Transcription Factors
1
2014
209
0.090
 Why?
Drug Monitoring
1
2016
401
0.090
 Why?
Antibodies, Monoclonal
2
2023
1505
0.090
 Why?
Disease-Free Survival
1
2014
770
0.090
 Why?
Xenograft Model Antitumor Assays
1
2015
936
0.090
 Why?
HLA-A Antigens
2
2024
52
0.090
 Why?
Connective Tissue
2
2022
38
0.090
 Why?
Enzyme Inhibitors
1
2015
821
0.090
 Why?
Oncogene Proteins, Fusion
1
2014
212
0.090
 Why?
Angiogenesis Inhibitors
1
2013
239
0.090
 Why?
Sirolimus
1
2013
282
0.080
 Why?
Curriculum
1
2017
1074
0.080
 Why?
Immunohistochemistry
3
2021
1723
0.080
 Why?
NF-kappa B
1
2013
667
0.080
 Why?
Clinical Trials, Phase I as Topic
2
2019
50
0.070
 Why?
Signal Transduction
3
2026
5223
0.070
 Why?
Neoplasm Grading
2
2018
311
0.060
 Why?
Randomized Controlled Trials as Topic
1
2013
1751
0.060
 Why?
CD3 Complex
1
2026
112
0.060
 Why?
Myeloid Differentiation Factor 88
1
2026
119
0.060
 Why?
Chromones
1
2024
43
0.050
 Why?
Career Mobility
1
2025
68
0.050
 Why?
Ifosfamide
1
2024
39
0.050
 Why?
DNA Copy Number Variations
1
2025
188
0.050
 Why?
Microsatellite Instability
1
2024
55
0.050
 Why?
Anilides
1
2024
84
0.050
 Why?
Adolescent
4
2021
22573
0.050
 Why?
Morpholines
1
2024
130
0.050
 Why?
Cohort Studies
1
2014
6032
0.050
 Why?
Frameshift Mutation
1
2023
31
0.050
 Why?
Activating Transcription Factor 4
1
2023
22
0.050
 Why?
Proteasome Inhibitors
1
2023
41
0.050
 Why?
Microsatellite Repeats
1
2024
157
0.050
 Why?
Gene Expression Profiling
2
2025
1777
0.050
 Why?
Quinolines
1
2024
190
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
67
0.050
 Why?
Workload
1
2025
169
0.050
 Why?
Valine
1
2023
83
0.050
 Why?
Disease Progression
2
2022
2865
0.050
 Why?
Amyloid Precursor Protein Secretases
1
2023
78
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
155
0.050
 Why?
Cell Differentiation
2
2021
2050
0.050
 Why?
Pyridines
1
2026
609
0.040
 Why?
Chemical and Drug Induced Liver Injury
1
2023
138
0.040
 Why?
Observational Studies as Topic
1
2022
134
0.040
 Why?
Killer Cells, Natural
1
2025
481
0.040
 Why?
Gastrointestinal Hemorrhage
1
2022
138
0.040
 Why?
Neoplasm Proteins
1
2024
442
0.040
 Why?
Cell Movement
1
2025
961
0.040
 Why?
DNA Methylation
1
2026
690
0.040
 Why?
Piperazines
1
2023
375
0.040
 Why?
Cytokines
2
2019
2069
0.040
 Why?
T-Cell Antigen Receptor Specificity
1
2019
45
0.040
 Why?
Genomics
1
2025
830
0.040
 Why?
Mice, Nude
1
2021
680
0.040
 Why?
Reactive Oxygen Species
1
2022
611
0.040
 Why?
Tumor Suppressor Protein p53
1
2023
534
0.040
 Why?
Prospective Studies
2
2022
8075
0.040
 Why?
Cross-Over Studies
1
2021
610
0.040
 Why?
Cell Lineage
1
2021
378
0.040
 Why?
Oncolytic Viruses
1
2018
8
0.030
 Why?
Oncolytic Virotherapy
1
2018
13
0.030
 Why?
Organ Sparing Treatments
1
2018
37
0.030
 Why?
Margins of Excision
1
2018
50
0.030
 Why?
Double-Blind Method
1
2023
2064
0.030
 Why?
SMARCB1 Protein
1
2018
34
0.030
 Why?
Radiotherapy, Adjuvant
1
2018
222
0.030
 Why?
SEER Program
1
2018
230
0.030
 Why?
Mice, Knockout
1
2024
3130
0.030
 Why?
DNA-Binding Proteins
1
2024
1482
0.030
 Why?
Syndrome
1
2018
381
0.030
 Why?
Germ-Line Mutation
1
2018
177
0.030
 Why?
Pedigree
1
2018
515
0.030
 Why?
Cell- and Tissue-Based Therapy
1
2017
78
0.030
 Why?
Models, Molecular
1
2021
1599
0.030
 Why?
Rats, Sprague-Dawley
1
2021
2525
0.030
 Why?
Immune System
1
2017
180
0.030
 Why?
Risk
1
2018
923
0.030
 Why?
Surgical Procedures, Operative
1
2018
271
0.030
 Why?
Population Surveillance
1
2018
484
0.030
 Why?
PAX3 Transcription Factor
1
2014
17
0.030
 Why?
Incidence
1
2021
2933
0.030
 Why?
Radiation
1
2014
24
0.030
 Why?
Cell Proliferation
1
2021
2514
0.030
 Why?
Forkhead Box Protein O1
1
2014
35
0.030
 Why?
Mutation, Missense
1
2015
335
0.020
 Why?
Cell Cycle Checkpoints
1
2014
97
0.020
 Why?
Transplantation, Heterologous
1
2013
170
0.020
 Why?
Chondrocytes
1
2015
232
0.020
 Why?
Program Evaluation
1
2017
944
0.020
 Why?
Rats
1
2021
5585
0.020
 Why?
Education, Medical, Graduate
1
2017
562
0.020
 Why?
Sensitivity and Specificity
1
2016
2000
0.020
 Why?
Phenotype
1
2019
3170
0.020
 Why?
Communication
1
2017
977
0.020
 Why?
Disease Models, Animal
1
2021
4568
0.020
 Why?
Polymerase Chain Reaction
1
2013
1043
0.020
 Why?
Adaptation, Physiological
1
2014
560
0.020
 Why?
Recurrence
1
2013
1139
0.020
 Why?
Dose-Response Relationship, Drug
1
2013
2028
0.020
 Why?
Genotype
1
2013
1857
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2017
1420
0.020
 Why?
Reproducibility of Results
1
2016
3416
0.020
 Why?
Biomarkers
1
2019
4302
0.020
 Why?
United States
1
2025
16123
0.020
 Why?
Child
2
2019
22739
0.020
 Why?
Polymorphism, Single Nucleotide
1
2013
2181
0.010
 Why?
Surveys and Questionnaires
1
2017
6085
0.010
 Why?
Child, Preschool
1
2019
11868
0.010
 Why?
Infant
1
2018
10090
0.010
 Why?
Wilky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (268) concept(s)
_
Co-Authors Expand Description
See all (31) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)